Bruises are a common side effect of injectable treatments, such as botulinum toxin and dermal fillers. In most cases, bruises are a natural part of the healing process, but they are troubling to patients eager to see immediate improvement in their appearances. That’s why experienced injectors are taking steps to identify those at the greatest risk for bruising and integrating new tools as well as pre-...
Bruises are a common side effect of injectable treatments, such as botulinum toxin and...
The medspa industry has seen explosive growth over the past decade, thanks to...
A picosecond‐domain laser with a 785nm wavelength has a special infinity for purple,...
Karen Horton, MD, a plastic surgeon in private practice in San Francisco, credits her...
Canfield Scientific’s VECTRA H2 offers an all-in-one portable lightweight 3D...
Topix Pharmaceuticals' Replenix Pure Hydration Plumping Lip Treatment Broad...
Capture consistent before-and-after images with FotoFinder’s new Automated...
Epionce Renewal Calming Cream from Episciences soothes sensitive, eczema-...
 The U.S. Food and Drug Administration (FDA) has granted clearance for Sebacia Microparticles for the treatment of mild-to-moderate inflammatory acne. The gold microparticles are used with a 1,064nm laser to selectively target the sebaceous glands. The FDA clearance is based on results from a U....
|
 Higher doses of Botox Cosmetic are well tolerated and offer better longevity than the traditional 20-unit dose, according the results of a new clinical study. Allergan conducted a trial to evaluate the duration of effect and safety of Botox Cosmetic at 40, 60 and 80 unit doses versus the 20-...
|
The U.S. Food and Drug Administration (FDA) has granted clearance for Sebacia Microparticles for the treatment of mild-to-moderate inflammatory acne. The gold microparticles are used with a 1,064nm laser to selectively target the sebaceous glands. The FDA clearance is based on results from a U.S. pivotal, randomized, controlled, blinded trial evaluating 168 patients with mild-to-moderate acne using either Sebacia Microparticles with laser or laser alone.
In this study, the Sebacia Microparticles treatment arm demonstrated a 53 percent median reduction in inflammatory lesion count, compared to 45 percent median reduction achieved by the laser treatment alone. The study achieved its primary endpoint of demonstrating non-inferiority at 12 weeks. It also achieved several secondary endpoints including 30.1 percent of patients treated with Sebacia Microparticles achieving a clear or almost clear IGA score (Investigator's Global Assessment of acne severity). All reported adverse events were of mild-to-moderate intensity. There were no severe adverse events nor were there any serious and/or unanticipated adverse events related to study treatment.
“The clinical results demonstrated by the U.S. pivotal study were...
Higher doses of Botox Cosmetic are well tolerated and offer better longevity than the traditional 20-unit dose, according the results of a new clinical study. Allergan conducted a trial to evaluate the duration of effect and safety of Botox Cosmetic at 40, 60 and 80 unit doses versus the 20-unit dose in patients with moderate-to-severe glabellar lines. The primary efficacy endpoint of ≥1 point improvement in Facial Wrinkle Scale (FWS) from baseline was met and was statistically significant for 40, 60 and 80 units versus 20 units in 226 subjects at 24 weeks.
Thirty-two percent of patients were responders at week 24 in the 40-unit group, 30.6 percent in the 60-unit group, and 38.5 percent in the 80-unit group as compared to 16 percent in the 20-unit group. For responders with a ≥1 point improvement, the time to return to baseline also demonstrated a dose-effect. The median time on the Kaplan-Meier curve was 19.7 weeks for 20 units and 24.0 weeks for 40 units, suggesting the median benefit of 40 units is between 20 and 24 weeks.
“These study results help us better understand the Botox Cosmetic dose duration of effect and confirm our hypothesis that higher doses of botulinum toxin produce a longer duration of...
Allergan has agreed to acquire Bonti, a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the acquisition, Allergan will obtain global rights to Bonti’s pipeline consisting of two botulinum neurotoxin serotype E (BoNT/E) programs currently in Phase 2 development: EB-001A (aesthetic) and EB-001T (therapeutic). The active ingredient in both programs, EB-001, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical profile, characterized by a rapid onset of action within 24 hours and a two- to four-week duration of effect. Bonti recently announced topline results of the first clinical study of EB-001 in glabellar frown lines. The study confirmed both the safety and efficacy of the differentiated profile.
“The acquisition of Bonti is a strategic investment for the future of our medical aesthetics business and has the potential to enhance our best-in-class medical aesthetics pipeline,” said Brent Saunders, chairman and CEO of Allergan. “With the medical aesthetics market vastly expanding, a fast-acting neurotoxin with a two- to four-week duration...
The American Society for Dermatologic Surgery (ASDS) and American Society for Dermatologic Surgery Association (ASDSA) were recognized with 14 awards—including three Platinums—in the 2015 MarCom Awards.
The MarCom Awards competition is administered and judged by the Association of Marketing and Communication Professionals, selecting winners “whose work serves as a benchmark for the industry.” The 2015 competition received about 6,500 entries representing more than a dozen countries.
The Platinum Award—MarCom’s top honor—was presented to ASDS in three categories: Currents... more »
Merz Aesthetics has begun commercial shipment of the Cellfina System, indicated for long-term improvement in the appearance of cellulite in the buttocks and thighs, to aesthetic practices in the U.S.
Cellfina combines proprietary technology with minimally invasive subcision to treat the primary structural cause of dimpled cellulite. Results of the procedure last at least two years—in clinical trials, patient satisfaction with their treatment results improved from 94% at one year to 96% at the two-year mark. The most common side effects reported were soreness, tenderness and bruising... more »
